×
  • Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    US Mastitis Market

    ID: MRFR/Pharma/11749-HCR
    100 Pages
    Garvit Vyas
    October 2025

    US Mastitis Market Research Report: By Type (Contagious Mastitis, Environmental Mastitis, Opportunist Mastitis, Non-Infectious Mastitis, Infectious Mastitis), By Treatment (Antibiotics, Vaccines, Pain Relievers) and By End User (Veterinary Centers, Hospital & Clinics) - Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    US Mastitis Market Infographic
    Purchase Options

    US Mastitis Market Summary

    As per MRFR analysis, the US mastitis market Size was estimated at 5.79 USD Billion in 2024. The US mastitis market is projected to grow from 6.8 USD Billion in 2025 to 33.91 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 17.43% during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The US mastitis market is experiencing a transformative shift driven by technological advancements and changing consumer preferences.

    • The largest segment in the US mastitis market is the diagnostic technologies segment, which is witnessing a rising adoption rate.
    • The fastest-growing segment is the treatment options segment, reflecting a shift towards innovative solutions for mastitis management.
    • There is a notable focus on antibiotic stewardship, as stakeholders aim to reduce antibiotic use in dairy farming.
    • Key market drivers include increasing awareness of animal health and the economic impact of mastitis on dairy production.

    Market Size & Forecast

    2024 Market Size 5.79 (USD Billion)
    2035 Market Size 33.91 (USD Billion)

    Major Players

    Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Cegelec (FR), Vetoquinol (FR), Huvepharma (BG), Dechra Pharmaceuticals (GB), Phibro Animal Health (US)

    US Mastitis Market Trends

    The mastitis market is currently experiencing notable developments driven by various factors. The increasing awareness of animal health and welfare has led to a heightened focus on effective mastitis management strategies. Farmers and veterinarians are increasingly adopting advanced diagnostic tools and treatment options to address this prevalent issue in dairy herds. This shift is likely influenced by the growing demand for high-quality dairy products, which necessitates the maintenance of optimal udder health. Furthermore, regulatory frameworks are evolving, emphasizing the importance of responsible antibiotic use, which may lead to the adoption of alternative therapies and preventive measures. In addition, technological advancements are playing a crucial role in shaping the mastitis market. Innovations in data analytics and monitoring systems are enabling farmers to track udder health more effectively, allowing for timely interventions. The integration of these technologies into routine farm management practices appears to enhance productivity and reduce economic losses associated with mastitis. As the industry continues to adapt to these changes, stakeholders are likely to explore new avenues for improving udder health, thereby fostering a more sustainable and profitable dairy sector.

    Rising Adoption of Diagnostic Technologies

    The mastitis market is witnessing a surge in the adoption of advanced diagnostic technologies. These tools enable early detection of mastitis, allowing for prompt treatment and management. Farmers are increasingly utilizing these technologies to monitor udder health, which may lead to improved milk quality and reduced economic losses.

    Focus on Antibiotic Stewardship

    There is a growing emphasis on responsible antibiotic use within the mastitis market. Regulatory bodies are advocating for reduced reliance on antibiotics, prompting the exploration of alternative treatment options. This trend may encourage the development of innovative therapies and preventive measures to manage mastitis effectively.

    Integration of Data Analytics in Farm Management

    The integration of data analytics into farm management practices is transforming the mastitis market. By leveraging data, farmers can make informed decisions regarding udder health management. This trend is likely to enhance productivity and contribute to the overall sustainability of dairy operations.

    US Mastitis Market Drivers

    Increasing Awareness of Animal Health

    The mastitis market is experiencing a surge in awareness regarding animal health, particularly among dairy farmers. This heightened consciousness is driven by educational initiatives and outreach programs aimed at promoting best practices in herd management. As farmers become more informed about the implications of mastitis on milk production and animal welfare, they are more likely to invest in preventive measures and treatment options. This trend is reflected in the growing demand for veterinary services and products designed to combat mastitis. In 2025, the market for mastitis-related products is projected to reach approximately $1.5 billion in the US, indicating a robust growth trajectory fueled by this increased awareness.

    Regulatory Support for Animal Welfare

    The mastitis market is influenced by increasing regulatory support aimed at enhancing animal welfare standards. In the US, various governmental bodies are implementing stricter regulations regarding the treatment and prevention of mastitis in dairy cattle. These regulations often require farmers to adopt more humane and effective practices, which in turn drives the demand for advanced mastitis management solutions. Compliance with these regulations necessitates investment in better diagnostic and treatment options, thereby propelling market growth. The financial implications of non-compliance can be substantial, further motivating farmers to prioritize mastitis management. This regulatory environment is expected to contribute to a market valuation of approximately $1.8 billion by 2026.

    Rising Demand for Organic Dairy Products

    The mastitis market is experiencing a shift in consumer preferences towards organic dairy products. As consumers become more health-conscious, there is a growing demand for milk and dairy products that are produced without the use of antibiotics and hormones. This trend is prompting dairy farmers to adopt more stringent mastitis management practices to ensure compliance with organic certification standards. Consequently, the market for mastitis management solutions is likely to expand as farmers seek effective ways to maintain herd health while meeting organic production requirements. The organic dairy segment is projected to grow at a CAGR of 8% over the next five years, indicating a robust opportunity for the mastitis market.

    Economic Impact of Mastitis on Dairy Production

    The mastitis market is significantly affected by the economic implications of mastitis on dairy production. Mastitis not only leads to decreased milk yield but also increases veterinary costs and reduces the overall profitability of dairy operations. The financial burden associated with mastitis can be substantial, with estimates suggesting that it costs the US dairy industry over $2 billion annually. This economic impact drives farmers to seek effective solutions for mastitis prevention and treatment, thereby stimulating growth in the mastitis market. As awareness of these economic factors continues to rise, investments in mastitis management technologies and practices are expected to increase, further propelling market expansion.

    Technological Advancements in Treatment Options

    The mastitis market is witnessing significant advancements in treatment technologies, which are reshaping the landscape of mastitis management. Innovations such as targeted therapies and improved formulations of existing treatments are becoming more prevalent. These advancements not only enhance the efficacy of mastitis treatments but also reduce the time required for recovery, thereby minimizing economic losses for dairy farmers. The introduction of new diagnostic tools that allow for quicker identification of mastitis cases is also contributing to this trend. As a result, the market is expected to grow at a CAGR of around 6% over the next five years, reflecting the impact of these technological improvements on the mastitis market.

    Market Segment Insights

    By Type: Bovine Contagious Mastitis (Largest) vs. Bovine Environmental Mastitis (Fastest-Growing)

    The market share distribution in the US mastitis market shows that Bovine Contagious Mastitis holds the largest share, reflecting its significant impact on dairy production and animal health. In contrast, Bovine Environmental Mastitis is emerging rapidly, contributing to an increasing share of the market due to heightened awareness about environmental factors affecting bovine health and productivity. Growth trends indicate that while Bovine Contagious Mastitis remains dominant due to ongoing veterinary attention and treatment advancements, Bovine Environmental Mastitis is witnessing the fastest growth driven by rising investments in preventive measures and better management practices. The awareness campaigns focused on environmental hygiene and milking practices are also contributing to this upward trend.

    Bovine Contagious Mastitis (Dominant) vs. Bovine Environmental Mastitis (Emerging)

    Bovine Contagious Mastitis is characterized by a persistent prevalence among dairy herds, often linked to pathogens transmitted between animals. It necessitates robust interventions for effective management and control, which enhances its dominant market position. On the other hand, Bovine Environmental Mastitis, caused by pathogens in the cow's environment, is an emerging concern as it has gained significant focus recently due to the emphasis on improving overall farm hygiene. Both segments play crucial roles in shaping treatment strategies, but the growing recognition of environmental influence on mastitis prevalence is rapidly changing market dynamics.

    By Treatment: Bovine Antibiotics (Largest) vs. Bovine Vaccines (Fastest-Growing)

    Within the treatment segment of the US mastitis market, Bovine Antibiotics dominate the landscape, comprising a substantial portion of the overall market share. This segment's significance is largely attributed to its established usage in mastitis management, with veterinarians frequently prescribing antibiotics to treat infections in dairy cattle, ensuring the health and productivity of the herd. Conversely, Bovine Vaccines are emerging as the fastest-growing segment, driven by an increasing awareness of the preventive measures against mastitis. The demand for vaccines is gaining traction due to the growing emphasis on herd health and the push for antibiotic stewardship among livestock producers. This growth is likely to be supported by advancements in vaccine development, resulting in more effective immunization strategies.

    Bovine Antibiotics (Dominant) vs. Bovine Vaccines (Emerging)

    Bovine Antibiotics play a dominant role in the US mastitis market due to their critical function in treating infected dairy cattle, thereby reducing the economic impact of mastitis on farms. This segment includes various formulations, such as intramammary and systemic antibiotics, tailored to effectively combat mastitis. On the other hand, Bovine Vaccines are gaining ground as an emerging solution. They are designed not only to prevent mastitis but also to improve the overall health and milk production of dairy herds. The growing demand for sustainable farming practices is intensifying interest in vaccines, leading to increased research and development efforts in this area, thereby positioning Bovine Vaccines as a viable alternative to antibiotics.

    By End User: Veterinary Centers (Largest) vs. Hospital & Clinics (Fastest-Growing)

    In the US mastitis market, the distribution of market share among the end user segments reveals that Veterinary Centers hold a significant portion of the market, reflecting their vital role in the treatment and management of mastitis. These centers are equipped with specialized knowledge and tools to diagnose and treat mastitis effectively, catering to a broad client base of livestock producers and dairy farmers. On the other hand, Hospital & Clinics are emerging as the fastest-growing segment within this market. This surge can be attributed to the increasing awareness of mastitis management, advancements in veterinary medicine, and a rising number of veterinary professionals opting to work in clinical settings. The integration of new treatment modalities and enhanced veterinary services is strengthening the foothold of this segment in the marketplace.

    Veterinary Centers (Dominant) vs. Hospital & Clinics (Emerging)

    Veterinary Centers are positioned as the dominant players in the US mastitis market, offering comprehensive services that address the needs of both small and large-scale dairy operations. They provide specialized care, diagnostic services, and treatments tailored to manage mastitis, usually employing advanced techniques that ensure effective results. This segment is characterized by a strong focus on customer relationships and long-term partnerships with dairy producers. Conversely, Hospitals & Clinics represent an emerging segment that is gaining traction due to the increasing demand for specialized veterinary care. They are expanding their services to include innovative treatment approaches and preventive care, driven by the growing recognition of the economic impact of mastitis on dairy profitability. These facilities are increasingly adopting modern technology to improve treatment efficacy and enhance patient outcomes.

    Get more detailed insights about US Mastitis Market

    Key Players and Competitive Insights

    The mastitis market exhibits a competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on sustainability. Key players such as Zoetis (US), Merck Animal Health (US), and Elanco Animal Health (US) are at the forefront, each employing distinct strategies to enhance their market presence. Zoetis (US) emphasizes innovation in product development, particularly in the realm of vaccines and diagnostics, which appears to be a critical driver of their growth. Meanwhile, Merck Animal Health (US) focuses on expanding its portfolio through strategic acquisitions, thereby enhancing its capabilities in addressing mastitis. Elanco Animal Health (US) is also notable for its commitment to sustainability, integrating environmentally friendly practices into its operations, which resonates well with current market demands.

    The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market needs. The competitive structure of the mastitis market is moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Zoetis (US) and Merck Animal Health (US) suggests a trend towards consolidation, as these firms leverage their resources to gain a competitive edge.

    In October 2025, Zoetis (US) announced a partnership with a leading agricultural technology firm to develop a digital platform aimed at improving mastitis detection and management on dairy farms. This strategic move is likely to enhance Zoetis's product offerings and position them as a leader in digital solutions within the mastitis market. The integration of technology into traditional veterinary practices could significantly improve outcomes for dairy farmers, thereby reinforcing Zoetis's market position.

    In September 2025, Merck Animal Health (US) completed the acquisition of a smaller biotech company specializing in mastitis treatment solutions. This acquisition is expected to bolster Merck's product pipeline and expand its reach in the mastitis segment, indicating a proactive approach to enhancing its competitive stance. By integrating innovative treatments into its portfolio, Merck is likely to address unmet needs in the market, thereby attracting a broader customer base.

    In August 2025, Elanco Animal Health (US) launched a new line of sustainable mastitis treatment products, which are designed to minimize environmental impact while maintaining efficacy. This initiative aligns with the growing consumer demand for sustainable agricultural practices and positions Elanco favorably among environmentally conscious consumers. The launch reflects a broader trend in the industry towards sustainability, which is becoming a key differentiator in the market.

    As of November 2025, the mastitis market is increasingly defined by trends such as digitalization, sustainability, and the integration of artificial intelligence in product development. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing product offerings. Looking ahead, it appears that competitive differentiation will increasingly pivot from price-based strategies to a focus on innovation, technological advancements, and supply chain reliability, as companies strive to meet evolving consumer expectations and regulatory standards.

    Key Companies in the US Mastitis Market market include

    Industry Developments

    Recent developments in the US Mastitis Market indicate a dynamic and evolving landscape, with continued focus on combating this significant dairy cattle health issue. Companies such as Zoetis, Merck Animal Health, and Elanco Animal Health have been actively engaging in Research and Development to enhance treatment options for mastitis, which is critical for maintaining herd health and productivity.

    In August 2023, Genus announced a partnership with Alltech for the implementation of microbiome-based solutions aimed at reducing cases of mastitis. Reports also indicate a growing trend towards the use of advanced probiotics and vaccines to address mastitis, showcasing innovations from firms like Vetoquinol and Boehringer Ingelheim.

    In terms of financial movement, the valuation of companies involved in the US Mastitis Market has shown considerable growth due to rising awareness of animal health and welfare. Over the past few years, the market has witnessed a steady increase in investments and mergers, with notable activities reported, such as Westway Feed Products seeking to enhance its product line through a strategic acquisition in July 2022.

    Additionally, the Agricultural Research Service has implemented programs aimed at improving early detection and treatment methodologies, further solidifying the proactive approach within the market.

    Future Outlook

    US Mastitis Market Future Outlook

    The mastitis market is projected to grow at a 17.43% CAGR from 2024 to 2035, driven by advancements in treatment technologies and increasing awareness among dairy farmers.

    New opportunities lie in:

    • Development of mobile diagnostic tools for early mastitis detection.
    • Investment in automated milking systems to reduce infection rates.
    • Expansion of telehealth services for veterinary consultations on mastitis management.

    By 2035, the mastitis market is expected to achieve substantial growth, driven by innovative solutions and increased market demand.

    Market Segmentation

    US Mastitis Market Type Outlook

    • Bovine Contagious Mastitis
    • Bovine Environmental Mastitis
    • Bovine Opportunist Mastitis
    • Human Non-Infectious Mastitis
    • Human Infectious Mastitis

    US Mastitis Market End User Outlook

    • Veterinary Centers
    • Hospital & Clinics

    US Mastitis Market Treatment Outlook

    • Bovine Antibiotics
    • Bovine Vaccines
    • Human Pain Relievers
    • Human Antibiotics

    Report Scope

    MARKET SIZE 2024 5.79(USD Billion)
    MARKET SIZE 2025 6.8(USD Billion)
    MARKET SIZE 2035 33.91(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 17.43% (2024 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    Market Forecast Period 2025 - 2035
    Historical Data 2019 - 2024
    Market Forecast Units USD Billion
    Key Companies Profiled Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Cegelec (FR), Vetoquinol (FR), Huvepharma (BG), Dechra Pharmaceuticals (GB), Phibro Animal Health (US)
    Segments Covered Type, Treatment, End User
    Key Market Opportunities Advancements in diagnostic technologies enhance early detection and treatment options in the mastitis market.
    Key Market Dynamics Rising demand for innovative treatments drives competition and regulatory scrutiny in the mastitis market.
    Countries Covered US

    Leave a Comment

    FAQs

    What is the expected market size of the US Mastitis Market in 2024?

    The US Mastitis Market is expected to be valued at 5.5 billion USD in 2024.

    What will be the market valuation of the US Mastitis Market by 2035?

    By 2035, the US Mastitis Market is projected to reach a valuation of 9.5 billion USD.

    What is the expected CAGR for the US Mastitis Market from 2025 to 2035?

    The expected Compound Annual Growth Rate (CAGR) for the US Mastitis Market from 2025 to 2035 is 5.094 percent.

    Which type of mastitis holds the largest market value in 2024?

    In 2024, infectious mastitis holds the largest market value at 2.5 billion USD.

    How is the market segment for contagious mastitis expected to grow by 2035?

    The market segment for contagious mastitis is expected to grow from 1.2 billion USD in 2024 to 2.1 billion USD by 2035.

    Who are the major players in the US Mastitis Market?

    Key players in the US Mastitis Market include Genus, Zoetis, Merck Animal Health, and Elanco Animal Health.

    What is the market size for environmental mastitis in 2035?

    The market size for environmental mastitis is projected to reach 1.9 billion USD by 2035.

    What challenges does the US Mastitis Market currently face?

    The US Mastitis Market faces challenges such as increasing antibiotic resistance and the need for innovative treatment solutions.

    What opportunities for growth exist within the market?

    Opportunities for growth in the US Mastitis Market include advancements in dairy farming technologies and increased awareness of animal health.

    Is there a significant market share for non-infectious mastitis by 2035?

    Yes, the market for non-infectious mastitis is expected to increase to 1.5 billion USD by 2035.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions